Biomarker Testing for Cancer Treatment
A co-created guide by and for patient advocates and organizations, dedicated to empowering patients with essential biomarker testing information.
Guiding Informed Decisions
This resource aims to simplify access to biomarker testing information, prevent the need to start from scratch, and support patient advocates and organizations in helping patients find the right information and make informed decisions and actions at the right time regarding biomarker testing.
This resource is part of a broader suite of adaptable resources aimed at supporting patients along their healthcare pathway. Access the Targeted Therapy for Cancer Treatment resource and the Precision Medicine Questions & Answers (Q&A) Resource Builder .
This resource features:
Extensive Resources
Provides a wealth of information on biomarker testing.
Established Best Practices
Based on proven methods so you don’t have to start from scratch.
Established Best Practices
Designed to be easily understood by all.
Flexible Format
Easy to adapt and use.
It can be used to:
Update existing biomarker testing resources, ensuring that all the crucial elements are covered
Create a new biomarker testing resource by adapting this backbone resource to the relevant country and disease.
Access all adaptable resources for patients and patient organizations on Precision Medicine Synapse
This adaptable resource is available in multiple languages
ALK+ UK adapted the Biomarker Testing for Cancer Treatment resource.
View the adapted resource and read a testimonial from Debra Montague, who shares insights on the resource’s value and impact.
Cancer care is supposed to involve shared decision making, so the patient needs to be informed very well in order to contribute to those decisions. We are giving them the tools to become an expert in their own condition.
Debra Montague
Chairman and Founder of ALK Positive UK
Discover all adapted resources from the Biomarker Testing Guide
Interested in adapting this resource?
Building on Best Practices Through Community Collaboration
FT3 contributors collaborated in the identification of good practices and learnings with the aim of making them replicable through practical and actionable tools and resources. By doing so, FT3 acts as a catalyst of best practices: we aggregate them and build on them through multi-stakeholder collaboration, and we make them available by reducing the burden of developing a new resource.
This is the result of the aggregation of resources originally developed by our friends LUNGevity, Lung Cancer Europe, the National Cancer Institute, and the Research Advocacy Network which emerged as good resources in terms of scientific credibility, patient centricity, plain language, and ease of use. We thank them for their good practice inspiration.